Literature DB >> 1915307

Sequence-independent RNA cleavages generate the primers for plus strand DNA synthesis in hepatitis B viruses: implications for other reverse transcribing elements.

D D Loeb1, R C Hirsch, D Ganem.   

Abstract

Reverse transcription of RNA into duplex DNA requires accurate initiation of both minus and plus strand DNA synthesis; this in turn requires the generation of specific primer molecules. We have examined plus strand primer generation in the hepatitis B viruses, small DNA viruses that replicate via reverse transcription. The plus strand primer in these viruses is a short capped RNA derived from the 5' end of the RNA template by cleavage at a specific set of sites. To elucidate the cleavage mechanism we constructed a series of viral mutants bearing alterations in and around the cleavage sites. Our results reveal that the cleavage reaction is sequence-independent and indicate that the cleavage sites are positioned by measurement of the distance from the 5' end of the RNA. Comparison of these findings with what is known about RNase H-mediated primer generation in retroviruses and other retroid elements suggests that, despite many divergent features, some common molecular features are preserved.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1915307      PMCID: PMC453082          DOI: 10.1002/j.1460-2075.1991.tb04917.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  41 in total

1.  Evidence that a capped oligoribonucleotide is the primer for duck hepatitis B virus plus-strand DNA synthesis.

Authors:  J M Lien; C E Aldrich; W S Mason
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

Review 2.  The molecular biology of the hepatitis B viruses.

Authors:  D Ganem; H E Varmus
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

3.  A cis-acting element within the 5' leader of a cytomegalovirus beta transcript determines kinetic class.

Authors:  A P Geballe; R R Spaete; E S Mocarski
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

4.  Reverse transcriptase associated with the biosynthesis of the branched RNA-linked msDNA in Myxococcus xanthus.

Authors:  S Inouye; M Y Hsu; S Eagle; M Inouye
Journal:  Cell       Date:  1989-02-24       Impact factor: 41.582

5.  Intrinsic properties of reverse transcriptase in reverse transcription. Associated RNase H is essentially regarded as an endonuclease.

Authors:  F Oyama; R Kikuchi; R J Crouch; T Uchida
Journal:  J Biol Chem       Date:  1989-11-05       Impact factor: 5.157

6.  Reconstitution in vitro of RNase H activity by using purified N-terminal and C-terminal domains of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Z Hostomsky; Z Hostomska; G O Hudson; E W Moomaw; B R Nodes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

7.  Reverse transcriptase.RNase H from the human immunodeficiency virus. Relationship of the DNA polymerase and RNA hydrolysis activities.

Authors:  E S Furfine; J E Reardon
Journal:  J Biol Chem       Date:  1991-01-05       Impact factor: 5.157

8.  Mapping the major transcripts of ground squirrel hepatitis virus: the presumptive template for reverse transcriptase is terminally redundant.

Authors:  G H Enders; D Ganem; H Varmus
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

9.  Transcripts and the putative RNA pregenome of duck hepatitis B virus: implications for reverse transcription.

Authors:  M Büscher; W Reiser; H Will; H Schaller
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

10.  The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription.

Authors:  R Bartenschlager; H Schaller
Journal:  EMBO J       Date:  1988-12-20       Impact factor: 11.598

View more
  57 in total

1.  Small DNA hairpin negatively regulates in situ priming during duck hepatitis B virus reverse transcription.

Authors:  Jeffrey W Habig; Daniel D Loeb
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Mutations that increase in situ priming also decrease circularization for duck hepatitis B virus.

Authors:  D D Loeb; R Tian
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Integration of hepadnavirus DNA in infected liver: evidence for a linear precursor.

Authors:  W Yang; J Summers
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  Base pairing among three cis-acting sequences contributes to template switching during hepadnavirus reverse transcription.

Authors:  Ning Liu; Ru Tian; Daniel D Loeb
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-10       Impact factor: 11.205

5.  When retroviral reverse transcriptases reach the end of their RNA templates.

Authors:  T B Fu; J Taylor
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

6.  A novel cis-acting element facilitates minus-strand DNA synthesis during reverse transcription of the hepatitis B virus genome.

Authors:  Myeong-Kyun Shin; Jehan Lee; Wang-Shick Ryu
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration.

Authors:  Colin A Bill; Jesse Summers
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-16       Impact factor: 11.205

8.  Genome-wide networks of amino acid covariances are common among viruses.

Authors:  Maureen J Donlin; Brandon Szeto; David W Gohara; Rajeev Aurora; John E Tavis
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

Review 9.  Animal models and the molecular biology of hepadnavirus infection.

Authors:  William S Mason
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

10.  Incorporation of eukaryotic translation initiation factor eIF4E into viral nucleocapsids via interaction with hepatitis B virus polymerase.

Authors:  Seahee Kim; Haifeng Wang; Wang-Shick Ryu
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.